{"id":"telbivudine-lamivudine-adefovir-enecavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatic flare"},{"rate":"3-5","effect":"Myopathy (telbivudine)"},{"rate":"1-3","effect":"Renal impairment (adefovir)"},{"rate":"1-5","effect":"Nausea"},{"rate":"1-3","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL374731","moleculeType":"Small molecule","molecularWeight":"242.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telbivudine, lamivudine, adefovir, and entecavir are antiviral agents that inhibit hepatitis B virus (HBV) reverse transcriptase, preventing viral DNA synthesis and replication. They are nucleoside or nucleotide analogues that get incorporated into the growing viral DNA chain, causing chain termination. These agents reduce HBV viral load and improve liver function in chronic hepatitis B patients.","oneSentence":"These nucleoside/nucleotide reverse transcriptase inhibitors block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:25.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"Hepatitis B with compensated liver disease"},{"name":"Hepatitis B with decompensated cirrhosis (entecavir, adefovir)"}]},"trialDetails":[{"nctId":"NCT01693679","phase":"PHASE4","title":"Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis","status":"UNKNOWN","sponsor":"Shao-quan Zhang","startDate":"2012-09","conditions":"HBV-related Liver Cirrhosis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["no."],"phase":"marketed","status":"active","brandName":"Telbivudine, Lamivudine, Adefovir ,Enecavir","genericName":"Telbivudine, Lamivudine, Adefovir ,Enecavir","companyName":"Shao-quan Zhang","companyId":"shao-quan-zhang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These nucleoside/nucleotide reverse transcriptase inhibitors block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection, Hepatitis B with compensated liver disease, Hepatitis B with decompensated cirrhosis (entecavir, adefovir).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}